IL2 and peeling skin syndrome: In this randomized clinical trial of 60 patients with pSS, patients receiving LD-IL-2 had significant improvement in their European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index scores at week 24, and the immunological analysis found that LD-IL-2 induced expansion of regulatory lymphocytes, leading to the restoration of immune homeostasis in pSS.